

TRADE/2322 - Meeting with US Chambers of Commerce

Meeting date and place

Meeting held on 01/04/2022 10:00

Participating organisation(s) representative(s)

Art.4(1)(b)	Pfizer Inc.	Participant
Art.4(1)(b)	Eli Lilly and Company	Participant
Art.4(1)(b)	Novartis International AG	Participant
Art.4(1)(b)	Global Innovation Policy Center	Participant, Requester
Art.4(1)(b)	MSD (Europe), Inc. (Merck Sharp & Dohme)	Participant
Art.4(1)(b)	Pharmaceutical Research and Manufacturers of America	Participant

Main issues discussed

At the request of the US Chamber and its members, the Commission presented the state of play of the talks in the WTO with regard to the proposal for a waiver of IP rights with regard to COVID-19 products. US Chamber members expressed concerns with the so-called 'Quad' text. The US Chamber members also reiterated their general concerns with the waiver proposal as endangering the ongoing research and innovation into COVID-19 and other therapies as well as the ongoing collaborations.

Directorate or unit

TRADE.B.3

Internal participants

Art.4(1)(b)	TRADE B/3	Art.4(1)(b) @ec.europa.eu	Notetaker, Participant
Art.4(1)(b)	TRADE B/3	Art.4(1)(b) @ec.europa.eu	Notetaker, Participant

Author(s) of minutes

Art.4(1)(b)

Validator and validation date

Art.4(1)(b)